BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leskela S, Romero I, Rosa-Rosa JM, Caniego-Casas T, Cristobal E, Pérez-Mies B, Gutierrez-Pecharroman A, Santón A, Ojeda B, López-Reig R, Palacios-Berraquero ML, Andrada E, Montes S, Pastor F, Gomez MC, López-Guerrero JA, Poveda A, Palacios J. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification. Am J Surg Pathol 2020;44:982-90. [PMID: 32384322 DOI: 10.1097/PAS.0000000000001478] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Similä-maarala J, Soovares P, Pasanen A, Ahvenainen T, Vahteristo P, Bützow R, Lassus H. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma. Gynecologic Oncology 2022. [DOI: 10.1016/j.ygyno.2022.03.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hollis RL, Stanley B, Thomson JP, Churchman M, Croy I, Rye T, Bartos C, Nussey F, Mackean M, Meynert AM, Semple CA, Gourley C, Herrington CS. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. NPJ Precis Oncol 2021;5:47. [PMID: 34079052 DOI: 10.1038/s41698-021-00187-y] [Reference Citation Analysis]
3 Davila JI, Chanana P, Sarangi V, Fogarty ZC, Weroha SJ, Guo R, Goode EL, Huang Y, Wang C. Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Med Genomics 2021;14:165. [PMID: 34158040 DOI: 10.1186/s12920-021-01017-7] [Reference Citation Analysis]
4 Li H, Wang S, Yao Q, Liu Y, Yang J, Xu L, Yang G. A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer. Front Oncol 2021;11:624240. [PMID: 34123783 DOI: 10.3389/fonc.2021.624240] [Reference Citation Analysis]
5 Rabban JT, Chen L, Devine WP. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.02.003] [Reference Citation Analysis]
6 Chen S, Li Y, Qian L, Deng S, Liu L, Xiao W, Zhou Y. A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer. Front Oncol 2021;11:668151. [PMID: 34150634 DOI: 10.3389/fonc.2021.668151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Hollis RL, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat Commun 2020;11:4995. [PMID: 33020491 DOI: 10.1038/s41467-020-18819-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
8 Barnes BM, Nelson L, Tighe A, Burghel GJ, Lin IH, Desai S, McGrail JC, Morgan RD, Taylor SS. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med 2021;13:140. [PMID: 34470661 DOI: 10.1186/s13073-021-00952-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Köbel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers 2022;14:416. [DOI: 10.3390/cancers14020416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]